Physician profile
Jaaska Cather
NPI 1255712287
$1,699.70
in general payments reported to CMS, 2019-2025
21 companies · $585 in 2025
The $585 reported for 2025 was more than what a typical Psychiatric/Mental Health, Geropsychiatric provider received nationally (typical 2025 total: $510).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $115 · 2023: $433 · 2024: $567 · 2025: $585.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,585.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,584.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $267.83 | 2023-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $221.56 | 2023-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Teva Pharmaceuticals USA, INC. | $182.99 | 2023-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Alkermes, INC. | $143.26 | 2023-2025 | Lybalvi, Aristada |
| Vanda Pharmaceuticals INC. | $124.20 | 2024-2025 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $111.83 | 2024-2025 | Caplyta |
| Axsome Therapeutics, INC. | $102.67 | 2022-2024 | Sunosi, Auvelity |
| Supernus Pharmaceuticals, INC. | $100.20 | 2023-2025 | Qelbree, Qelbree |
| Neurocrine Biosciences, INC. | $80.75 | 2022-2025 | Ingrezza |
| Bausch Health US, LLC | $56.45 | 2023-2025 | Aplenzin |
| Corium, LLC | $46.79 | 2025 | Azstarys |
| Almatica Pharma LLC | $41.50 | 2022-2023 | Sertraline Hcl, Loreev Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $36.33 | 2025 | Trintellix |
| Ironshore Pharmaceuticals INC. | $32.76 | 2022-2023 | Jornay Pm |
| Abbvie INC. | $31.93 | 2023-2024 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $23.51 | 2022 | |
| Neos Therapeutics, LP | $23.19 | 2024 | Adzenys Xr-Odt |
| Tris Pharma INC | $21.26 | 2024 | Dyanavel Xr |
| Collegium Pharmaceutical, INC. | $18.04 | 2025 | Jornay Pm |
| Vertical Pharmaceuticals, LLC | $17.41 | 2024 | Relexxii |
| Brainsway USA INC | $15.24 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaaska Cather listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.